Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) in a report released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $57.00 price target on the specialty pharmaceutical company's stock.

Several other research analysts have also issued reports on SUPN. Cowen reaffirmed a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock traded up $0.13 during mid-day trading on Monday, hitting $37.05. 869,473 shares of the stock traded hands, compared to its average volume of 533,022. Supernus Pharmaceuticals has a 52-week low of $25.53 and a 52-week high of $39.37. The stock has a market cap of $2.05 billion, a P/E ratio of 34.63 and a beta of 0.90. The stock's fifty day moving average is $36.21 and its two-hundred day moving average is $33.04.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Supernus Pharmaceuticals's revenue for the quarter was up 14.2% compared to the same quarter last year. As a group, equities analysts forecast that Supernus Pharmaceuticals will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jack A. Khattar sold 125,000 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now owns 13,315 shares in the company, valued at $487,595.30. The trade was a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 in the last 90 days. Insiders own 9.30% of the company's stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 398 shares during the period. Meeder Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after acquiring an additional 352 shares during the period. Kennebec Savings Bank purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth approximately $103,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $174,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.